A fixed-dose combination (FDC) of a benzodiazepine (Clonazepam) and a selective serotonin reuptake inhibitor (SSRI) (Escitalopram). Clonazepam provides rapid anxiolytic, sedative, and anticonvulsant effects, while Escitalopram provides sustained antidepressant and anxiolytic effects by increasing synaptic serotonin. This combination is primarily used for the initial management of moderate to severe anxiety disorders with associated agitation, insomnia, or panic symptoms, leveraging the rapid onset of Clonazepam to bridge the 2-4 week latency period of Escitalopram.
Adult: Usually 1 tablet (Clonazepam 0.5mg + Escitalopram 5mg) once daily, preferably at bedtime to utilize clonazepam's sedative effect. May be increased to twice daily (morning and bedtime) in severe cases under close supervision. The clonazepam component should be used for the shortest duration necessary (typically 2-4 weeks).
Note: Take orally with or without food. Swallow whole with a glass of water. Taking at bedtime can minimize daytime drowsiness from clonazepam. Do not crush or chew. Avoid grapefruit juice (may inhibit CYP3A4, affecting clonazepam). Do not stop abruptly; clonazepam requires a gradual taper to avoid withdrawal syndrome.
The combination works via two distinct but complementary mechanisms. Escitalopram potently and selectively inhibits the presynaptic serotonin (5-HT) reuptake transporter (SERT), increasing serotonin concentration in the synaptic cleft, leading to adaptive changes in pre- and post-synaptic receptors over time, which is responsible for its antidepressant and anxiolytic effects. Clonazepam is a positive allosteric modulator of the GABA-A receptor, enhancing the inhibitory effect of the neurotransmitter GABA, resulting in rapid anxiolytic, sedative-hypnotic, muscle relaxant, and anticonvulsant effects.
Pregnancy: Category D (Clonazepam) and Category C (Escitalopram). Generally contraindicated, especially in first trimester. Clonazepam is associated with risk of congenital malformations (cleft lip/palate), floppy infant syndrome, and withdrawal in neonate. Escitalopram use in late pregnancy may lead to neonatal adaptation syndrome (respiratory distress, feeding difficulty, seizures). Use only if potential benefit justifies fetal risk. Consult obstetrician and psychiatrist.
Driving: Seriously impairs alertness, reaction time, and motor coordination, especially during initial treatment and dose adjustments. Patients should not drive or operate heavy machinery until their individual response is known and they are free from drowsiness/dizziness.
| Other CNS Depressants (Alcohol, Opioids, Barbiturates, other Benzodiazepines) | Additive CNS depression, respiratory depression, profound sedation, coma | Major |
| Monoamine Oxidase Inhibitors (MAOIs) - Phenelzine, Selegiline, Moclobemide | Risk of serotonin syndrome, hyperthermia, rigidity, autonomic instability | Contraindicated |
| Strong CYP2C19 Inhibitors (Omeprazole, Fluconazole, Fluvoxamine) | Increased escitalopram plasma levels, risk of toxicity | Moderate |
| Strong CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Ritonavir) | Increased clonazepam plasma levels, enhanced sedation | Moderate |
| Strong CYP3A4 Inducers (Rifampicin, Carbamazepine, Phenytoin, St. John's Wort) | Decreased clonazepam plasma levels, reduced efficacy, potential withdrawal | Moderate |
| Antiplatelets/Anticoagulants (Warfarin, Aspirin, NSAIDs) | Increased risk of bleeding due to SSRI effect on platelets | Moderate |
| Drugs prolonging QT interval (Class IA/III antiarrhythmics, Macrolides, Antipsychotics) | Additive risk of QT prolongation, torsades de pointes | Moderate |
| Lithium, Tramadol, Triptans, Linezolid | Increased risk of serotonin syndrome | Moderate |
Same composition (Clonazepam (0.5mg) + Escitalopram Oxalate (5mg)), different brands: